PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31567201-0	2021	Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer.	erlotinib	39-48	epidermal growth factor receptor	Homo sapiens	72-76	
31567201-2	2021	Erlotinib is a reversible epidermal growth factor receptor (EGFR) inhibitor, which was approved at its maximum tolerated dose of 150 mg/d determined from the initial phase I study.	erlotinib	0-9	epidermal growth factor receptor	Homo sapiens	26-58	
31567201-2	2021	Erlotinib is a reversible epidermal growth factor receptor (EGFR) inhibitor, which was approved at its maximum tolerated dose of 150 mg/d determined from the initial phase I study.	erlotinib	0-9	epidermal growth factor receptor	Homo sapiens	60-64